<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78877</article-id><article-id pub-id-type="doi">10.7554/eLife.78877</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-274381"><name><surname>Casillas-Espinosa</surname><given-names>Pablo Miguel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6199-9415</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278955"><name><surname>Anderson</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278956"><name><surname>Harutyunyan</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278957"><name><surname>Li</surname><given-names>Crystal</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278958"><name><surname>Lee</surname><given-names>Jiyoon</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278959"><name><surname>Braine</surname><given-names>Emma L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298008"><name><surname>Brady</surname><given-names>Rhys D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278960"><name><surname>Sun</surname><given-names>Mujun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208997"><name><surname>Huang</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278961"><name><surname>Barlow</surname><given-names>Christopher K</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278962"><name><surname>Shah</surname><given-names>Anup D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32332"><name><surname>Schittenhelm</surname><given-names>Ralf B</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243036"><name><surname>Mychasiuk</surname><given-names>Richelle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278963"><name><surname>Jones</surname><given-names>Nigel C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116118"><name><surname>Shultz</surname><given-names>Sandy R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2525-8775</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-171237"><name><surname>O’Brien</surname><given-names>Terence J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7198-8621</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Neuroscience</institution>, <institution>Monash University</institution>, <addr-line><named-content content-type="city">Melbourne</named-content></addr-line>, <country>Australia</country></aff><aff id="aff2"><institution content-type="dept">Department of Medicine</institution>, <institution>University of Melbourne</institution>, <addr-line><named-content content-type="city">Parkville</named-content></addr-line>, <country>Australia</country></aff><aff id="aff3"><institution content-type="dept">Monash Proteomics and Metabolomics Facility</institution>, <institution>Monash University</institution>, <addr-line><named-content content-type="city">Clayton</named-content></addr-line>, <country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-46365"><name><surname>Scharfman</surname><given-names>Helen</given-names></name><role>Reviewing editor</role><aff><institution>New York University Langone Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>pablo.casillas-espinosa@monash.edu</email> (PC);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>Terence.OBrien@monash.edu</email> (TO);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>09</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e78877</elocation-id><history><date date-type="received"><day>23</day><month>03</month><year>2022</year></date><date date-type="accepted"><day>08</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Casillas-Espinosa et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Casillas-Espinosa et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78877-v1.pdf"/><abstract><p>There are no pharmacological disease-modifying treatments that have an enduring effect to mitigate the seizures and comorbidities associated with established chronic temporal lobe epilepsy (TLE). Sodium selenate has been reported to have anti-epileptogenic effects if given before TLE onset. However, the majority of TLE patients already have established epilepsy when they present to the clinic. This study aimed to evaluate for disease modifying effects of sodium selenate treatment in the chronically epileptic rat post-status epilepticus (SE) model of drug-resistant TLE. Wistar rats underwent kainic acid-induced SE or sham. Ten-weeks post-SE, rats were randomly assigned to receive either sodium selenate, levetiracetam, or vehicle subcutaneous infusions continuously for 4 weeks. To evaluate the effects of the treatments, one week of continuous video-EEG was acquired before, during, and 4, 8 weeks post-treatment, followed by behavioral tests. Targeted and untargeted proteomics and metabolomics were performed on post-mortem brain tissue to identify potential pathways associated with modified disease outcomes. Telomere length has emerged as a potential biomarker of chronic brain conditions, was investigated as a novel surrogate marker of epilepsy disease severity in our current study. The results showed that sodium selenate treatment was associated with mitigation of measures of disease severity at 8 weeks post-treatment cessation; reducing the number of spontaneous seizures (p&lt; 0.05), cognitive dysfunction (p&lt; 0.05 in both novel object placement and recognition tasks), and sensorimotor deficits (p&lt; 0.01). Moreover, in the brain post-mortem selenate treatment was associated with increased protein phosphatase 2A (PP2A) expression, reduced hyperphosphorylated tau, and reversed telomere length shortening (p&lt; 0.05). Network medicine integration of multi-omics/ pre-clinical outcomes identified protein-metabolite modules positively correlated with the TLE phenotype. Our results provide evidence that treatment with sodium selenate results in a sustained disease-modifying effect in chronically epileptic rats in the post-KA SE model of TLE, including improved comorbid learning and memory deficits.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Rat</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>APP1087172</award-id><principal-award-recipient><name><surname>Casillas-Espinosa</surname><given-names>Pablo Miguel</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001782</institution-id><institution>University of Melbourne</institution></institution-wrap></funding-source><award-id>603834</award-id><principal-award-recipient><name><surname>Casillas-Espinosa</surname><given-names>Pablo Miguel</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007202</institution-id><institution>CIHR Skin Research Training Centre</institution></institution-wrap></funding-source><award-id>PTJ - 153051</award-id><principal-award-recipient><name><surname>Mychasiuk</surname><given-names>Richelle</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>Level 2 CDF</award-id><principal-award-recipient><name><surname>Shultz</surname><given-names>Sandy R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All procedures were approved by the Florey Animal Ethics Committee (ethics number 16-042-UM), adhered to the Australian code for the care and use of animals for scientific purposes and consistent with ARRIVE 2.0 guidelines</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All the metrodology and results form this work have been included in the manuscrit or as part of the supplementary material.Data has been deposited in Dryad https://doi.org/10.5061/dryad.37pvmcvnd</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Casillas-Espinosa PM</collab></person-group><year iso-8601-date="2022">2022</year><source>EEG and multi-omics data</source><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.5061/dryad.37pvmcvnd">https://dx.doi.org/10.5061/dryad.37pvmcvnd</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.37pvmcvnd</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-78877-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>